Published: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 1 to 20 of 20

Sort by

Keyword or reference number: RituximabRemove Keyword or reference number: Rituximab filter

Published guidance, NICE advice and quality standards
Title	Reference number	Published	Last updated
Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia (terminated appraisal)	TA703	26 May 2021	26 May 2021
Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma	TA649	23 September 2020	23 September 2020
Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab	TA629	13 May 2020	13 May 2020
Lenalidomide with rituximab for previously treated follicular lymphoma	TA627	7 April 2020	7 April 2020
Ibrutinib with rituximab for treating Waldenstrom's macroglobulinaemia (terminated appraisal)	TA608	30 October 2019	30 October 2019
Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia	TA561	27 February 2019	27 February 2019
Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal)	TA437	22 March 2017	22 March 2017
Skin involvement in systemic sclerosis: rituximab	ES7	7 March 2017	7 March 2017
Minimal change disease and focal segmental glomerulosclerosis in adults: rituximab	ES1	4 November 2016	4 November 2016
Autoimmune haemolytic anaemia: rituximab	ESUOM39	10 February 2015	10 February 2015
Immune (idiopathic) thrombocytopenic purpura: rituximab	ESUOM35	21 October 2014	21 October 2014
Non-Hodgkin's lymphoma: rituximab subcutaneous injection	ESNM46	9 September 2014	9 September 2014
Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis	TA308	26 March 2014	26 March 2014
Rituximab for the first-line treatment of stage III-IV follicular lymphoma	TA243	25 January 2012	25 January 2012
Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma	TA226	22 June 2011	22 June 2011
Bendamustine for the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab (terminated appraisal)	TA206	27 October 2010	27 October 2010
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor	TA195	25 August 2010	25 August 2010
Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia	TA193	28 July 2010	28 July 2010
Rituximab for the first-line treatment of chronic lymphocytic leukaemia	TA174	22 July 2009	22 July 2009
Rituximab for the treatment of relapsed or refractory stage 3 or 4 follicular non-Hodgkin's lymphoma	TA137	27 February 2008	27 February 2008

Results per page

10
25
50
All